Tirzepatide: the clinical name behind Mounjaro and why it matters

The misconception: 'Mounjaro' is the drug, tirzepatide is just a label

A lot of people assume the brand name carries the meaning and the INN is bureaucratic fine print. It's actually the other way round. Tirzepatide is the molecule; Mounjaro is Eli Lilly's commercial name for it in the UK. Every clinical trial, every NICE appraisal, every pharmacist's dispensing record and every prescriber's notes refer to tirzepatide. When the pivotal trial programme was registered and reported, it was registered under tirzepatide. If you want to read the evidence (and it's worth reading) that's the word you search for.

This matters practically too. When you transfer between services or your GP requests your records, the medicine appears as tirzepatide. Knowing that stops confusion about whether the pen in your fridge is the same treatment your consultant mentioned.

The distinction also helps you spot what's real. Counterfeit sellers often lean on the brand name alone; understanding that the clinical substance is tirzepatide, with a specific molecular mechanism and a specific licensed manufacturer, gives you a clearer filter for evaluating what any seller is actually offering. If you're interested in how tirzepatide is being studied in ongoing research settings, you can find out more about joining a tirzepatide clinical trial near you.

What 'dual-agonist' means in plain language, and why regulators care

The INN tirzepatide encodes something important: this molecule activates two receptors, not one. GLP-1 receptor agonists (the class that includes semaglutide (Wegovy)) work on a single pathway. Tirzepatide adds GIP receptor activation alongside it. Both receptors are involved in appetite regulation and blood-sugar control; stimulating them together produces effects that neither pathway alone achieves at the same level.

The trial results for tirzepatide reflect that dual action. In SURMOUNT-1, a large phase 3 study involving around 2,500 adults, average body-weight reduction at the 15 mg dose reached roughly 20–21% over 72 weeks, figures the NICE appraisal of tirzepatide (TA1026) weighed carefully before recommending it for NHS use.

From a regulatory standpoint, the MHRA licences a specific molecule with a specific pharmacological profile. That's why the INN carries legal weight. When a prescriber writes a prescription for tirzepatide (or reviews one) they are certifying that this particular mechanism is clinically appropriate for this particular patient.

How the clinical name appears in UK eligibility and prescribing

If you're researching Mounjaro as a weight-loss treatment, you'll quickly encounter criteria expressed in terms of tirzepatide: NICE TA1026 recommends tirzepatide for adults with a BMI of 35 or above plus at least one weight-related comorbidity. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. On the private side, the licensed eligibility runs slightly broader, adults with a BMI of 30 or above, or 27 and above where a weight-related condition is present.

None of that is decided by a form or an algorithm. A GPhC-registered prescriber reads the consultation, checks the clinical picture and makes the call. At nume, that happens the same working day your consultation is submitted, a named clinician, not automated software, reviews your answers. If you're curious about how our clinical team approaches these assessments, our clinical team page sets that out.

One practical point that surprises people: the starting dose of 2.5 mg exists to help your system adjust. It's not a therapeutic dose in the sense of producing significant weight change; its job is tolerability. The NHS tirzepatide guidance on the NHS medicines page for tirzepatide covers the dose-escalation schedule and what to expect at each stage, reading it alongside the Patient Information Leaflet in your pen's packaging is time well spent.

Why the clinical name matters when you're thinking about cost

You might be wondering whether knowing tirzepatide is the INN changes anything about what you'd actually pay. It does, indirectly. When Eli Lilly raised the UK list price of Mounjaro in September 2025, that change applied to tirzepatide in the Mounjaro formulation specifically, and investors tracking Mounjaro company stock noted the pricing move closely as a signal of Eli Lilly's commercial strategy. Generic tirzepatide does not exist in the UK at the time of writing; the branded Mounjaro pen is the only licensed supply.

That context is worth holding when you look at Mounjaro pricing from different providers. The molecule is identical regardless of where you buy it, what differs is whether the service around it includes a proper clinical assessment, a genuine prescription, and dispensing from a pharmacy you can verify on the GPhC register. A price that looks low often reflects something missing from the service, not a better deal on the medicine itself.

If you'd like to understand your options across weight-loss treatments more broadly, the weight-loss treatment overview sets out what's licensed in the UK and how each differs. When you're ready to have a prescriber review your situation, you can start your free consultation, there's no obligation, and the clinical review happens the same day.